Adaptive chemotherapy for ovarian cancer after platinum and PARP
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a personalized (adaptive) chemotherapy plan for people with certain types of ovarian/fallopian tube/peritoneal cancer who already had platinum chemotherapy and a PARP inhibitor. It’s for patients whose cancer came back after (or still responds to) prior platinum treatment and may help delay disease progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older
- You have high-grade serous or high-grade endometrioid cancer in the ovary, fallopian tube, or the lining around organs (peritoneum)
- Your last treatment included platinum chemotherapy (cisplatin or carboplatin), and you’ve also had a PARP inhibitor
- Your cancer responded to the most recent platinum treatment, and it came back at least 6 months after the last platinum cycle started
- You must have a measurable cancer spot on a recent scan (or meet CA125 progression rules if scans can’t measure it), and CA125 is at least 100
- You can come for frequent visits and blood tests around carboplatin treatment, and you have enough bone marrow, liver, and kidney function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a different way of giving chemotherapy to people with advanced ovarian cancer that didn't respond well to initial treatment. The goal is to see if changing the dose and schedule can improve outcomes.
This Phase 2 trial tests giving chemotherapy before surgery, then continuing two medicines afterward (olaparib and pembrolizumab). It’s designed for people with newly diagnosed Stage III/IV ovarian, fallopian tube, or primary peritoneal cancer who may benefit from tighter control of the disease.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This trial tests a new combination of drugs (trastuzumab rezetecan and carboplatin, with or without bevacizumab) against standard chemotherapy for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer. It’s for those who have already had platinum-based chemo and a PARP inhibitor, and whose cancer came back after a treatment-free interval of at least 6 months.
This trial tests if adding a drug called a PARP inhibitor (which helps block cancer cells from repairing themselves) to standard chemotherapy and heated chemotherapy during surgery (HIPEC) can work better together for ovarian cancer that has already been treated with initial chemo. It is for people with a specific type of advanced ovarian cancer who are planning surgery after chemo.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.